Autolus Q3 10-Q: Revenue Doubles to $41.2M, Net Loss Narrows to $55.1M
AUTL sits 18% above its 52-week low of $1.12 on elevated volume (3.5× avg).
Summary
Autolus' Q3 10-Q confirms product revenue doubled to $41.2M and the quarterly net loss narrowed to $55.1M, with $245.4M of cash and no going-concern warning. Gross margin improved sharply as cost of sales fell to 43% of revenue from 135%.
Key Events · Earnings and Guidance · AUTL
-
Q3 Revenue Doubles to $41.2M
Net product revenue rose 95% to $41.2M from $21.1M a year earlier, driven by more AUCATZYL doses at existing and new treatment centers plus the January 2026 U.K. launch.
-
Net Loss Narrows to $55.1M
Quarterly net loss fell from $79.1M; nine-month net loss was $165.8M versus $197.2M. Cost of sales dropped to 43% of revenue from 135% on manufacturing efficiency and the April 2026 restructuring.
-
Cash of $245.4M, No Going-Concern Doubt
Cash and equivalents of $245.4M plus $3.0M of marketable securities at September 30, 2026, with $25.0M of Tranche 2 notes available through January 30, 2027; management sees funding for at least twelve months.
-
Blackstone Warrant Expired Unexercised
The warrant for 3,265,306 ADSs at $7.35 per ADS expired on November 6, 2026 with no warrants remaining outstanding under it.
Analysis · AUTL · Life Sciences
The headline revenue figure was already out this morning, but the 10-Q is what shows the company can now fund itself: $245.4M of cash plus $3.0M of securities at September 30, no going-concern doubt, and a $25M Tranche 2 borrowing option through January 30, 2027. Just as important is the margin turn — cost of sales fell to 43% of revenue from 135% a year ago as manufacturing efficiency and the April restructuring took hold, and nine-month operating cash burn halved to $108.9M from $216.2M. Against that, interest expense rose to $14.5M for the quarter on the Blackstone/BioNTech royalty liabilities and the new Perceptive notes, and the company loses foreign private issuer status on January 1, 2027, which adds compliance cost. The Blackstone warrant for 3,265,306 ADSs at $7.35 expired unexercised on November 6, 2026, removing that overhang.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AUTL was trading at $1.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $351.3M. The 52-week trading range was $1.12 to $2.58. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.